Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors—is it time for a paradigm shift?

Immunotherapy has revolutionized cancer treatment during the last years. Several monoclonal antibodies that are specific for regulatory checkpoint molecules, that is, immune checkpoint inhibitors (ICIs), have been approved and are currently in use for various types of cancer in different lines of tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chatzidionysiou, Katerina, Liapi, Matina, Tsakonas, Georgios, Gunnarsson, Iva, Catrina, Anca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102438/
https://www.ncbi.nlm.nih.gov/pubmed/32989505
http://dx.doi.org/10.1007/s10067-020-05420-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102438/
https://www.ncbi.nlm.nih.gov/pubmed/32989505
http://dx.doi.org/10.1007/s10067-020-05420-w

Ejemplares similares